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Cardiac sarcoidosis is difficult to diagnose, often requiring expensive and inconvenient
advanced imaging techniques. Circulating exosomes contain genetic material, such as
microRNA (miRNA), that are derived from diseased tissues and may serve as potential dis-
ease-specific biomarkers. We thus sought to determine whether circulating exosome-
derived miRNA expression patterns would distinguish cardiac sarcoidosis (CS) from acute
myocardial infarction (AMI).
Methods
Plasma and serum samples conforming to CS, AMI or disease-free controls were procured
from the Biologic Specimen and Data Repository Information Coordinating Center reposi-
tory and National Jewish Health. Next generation sequencing (NGS) was performed on exo-
some-derived total RNA (n = 10 for each group), and miRNA expression levels were
compared after normalization using housekeeping miRNA. Quality assurance measures
excluded poor quality RNA samples. Differentially expressed (DE) miRNA patterns, based
upon >2-fold change (p < 0.01), were established in CS compared to controls, and in CS
compared to AMI. Relative expression of several DE-miRNA were validated by qRT-PCR.
Results
Despite the advanced age of the stored samples (~5–30 years), the quality of the exosome-
derived miRNA was intact in ~88% of samples. Comparing plasma exosomal miRNA in CS
versus controls, NGS yielded 18 DE transcripts (12 up-regulated, 6 down-regulated), includ-
ing miRNA previously implicated in mechanisms of myocardial injury (miR-92, miR-21) and
immune responses (miR-618, miR-27a). NGS further yielded 52 DE miRNA in serum
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exosomes from CS versus AMI: 5 up-regulated in CS; 47 up-regulated in AMI, including
transcripts previously detected in AMI patients (miR-1-1, miR-133a, miR-208b, miR-423,
miR-499). Five miRNAs with increased DE in CS included two isoforms of miR-624 and
miR-144, previously reported as markers of cardiomyopathy.
Conclusions
MiRNA patterns of exosomes derived from CS and AMI patients are distinct, suggesting
that circulating exosomal miRNA patterns could serve as disease biomarkers. Further stud-
ies are required to establish their specificity relative to other cardiac disorders.
Introduction
Sarcoidosis is an idiopathic granulomatous disorder that most often involves the lungs; how-
ever, cardiac complications of sarcoidosis are common and potentially life-threatening [1–3].
As recently as 20 years ago, the prevalence of cardiac involvement among patients with sar-
coidosis was estimated to be<5%. Since the advent of advanced cardiac imaging techniques,
such as cardiac magnetic resonance and positron emission tomography, the prevalence of car-
diac sarcoidosis (CS) is now estimated to be ~25%, which is in keeping with autopsy studies
[1]. However, the routine use of advanced imaging studies for the detection and monitoring of
CS is expensive, inconvenient, and carries some risk (e.g., radiation exposure during PET
scan). As such, there is an urgent need to develop a blood-based circulating biomarker for CS
detection.
Recent studies have reported that microvesicles released from diseased cells can be used to
detect and monitor the progression of disease. More specifically, small lipid vesicles (30–100
nm diameter) containing genetic cargo from the parent cell, referred to as exosomes, can be
detected in the circulation to identify various diseases, ranging from several different cancers
[4] to Alzheimer’s disease [5]. Microvesicles are abundant in the plasma, and these include rel-
atively large fragments of damaged cells and smaller exosomes that arise from endosomes con-
taining cell specific genetic and protein cargo. Exosomes arising from diseased cells often carry
a unique pattern of molecules including non-coding RNAs and proteins, which can be lever-
aged as biomarkers for disease diagnosis including heart disease. We previously showed that
CS patients have distinct circulating exosomal microRNA (miRNA) expression patterns com-
pared to sarcoidosis patients with no cardiac involvement [6].
CS often presents with chest pain and/or arrhythmias, clinical features shared with acute myo-
cardial infarction (AMI) [7–10], including relief of chest pain with nitrates [7], leading to an
expensive diagnostic evaluation for an ischemic etiology. In view of the need for better biomark-
ers, we sought to determine whether non-coding miRNA expression patterns in circulating exo-
somes could distinguish CS from AMI. We analyzed blood samples that were obtained from
prior National Institutes of Health (NIH)-sponsored clinical trials/studies. Despite variables relat-
ing to blood processing and duration of storage, the study validated previously reported circulat-
ing miRNA markers of AMI and identified some potential novel biomarkers for CS.
Materials and methods
Study samples
As existing, de-identified samples were received from their approved holders for further analy-
sis, this study was determined to require no further review nor approval by The Ohio State
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University Biomedical Sciences Institutional Review Board (# 2017E0627). We conducted a
retrospective study of 40 patients (20 discovery and 20 validation) with histologically proven
sarcoidosis who had clinical and radiographic evidence of CS, based upon established criteria
[2, 11, 12], compared to 20 patients (10 discovery and 10 validation) having a history of AMI,
and 20 age-matched, healthy, control subjects (10 discovery and 10 validation). Well-pheno-
typed, de-identified platelet-depleted plasma samples were collected within the scope of the
NIH-funded A Case Controlled Etiologic Study of Sarcoidosis [(ACCESS), 13] research study
from sarcoidosis case and matching controls; whereas, similarly characterized serum samples
were obtained as part of the NIH-funded Genomic Research in Alpha-1 Antitrypsin Defi-
ciency and Sarcoidosis [(GRADS), 12] and Thrombolysis in Myocardial Infarction [(TIMI II),
14] research studies. The ACCESS study was performed >20 years ago, and the plasma sam-
ples have been cryopreserved since that time. Likewise, the serum samples from the TIMI II
trial and GRADS study have been similarly stored and kept frozen over the>30 years and ~5
years since they were completed, respectively. These samples were obtained from the NIH Bio-
logic Specimen and Data Repository Information Coordinating Center (BioLINCC) repository
and from National Jewish Health.
Exosomal fraction isolation
Before exosome isolation, the plasma/serum samples were spun at 10,000 x g at 4˚C for 10
minutes to remove cell debris. The exosomal fraction was then enriched from either 250 μl of
clarified plasma or serum using the Total Exosome Isolation kits (for plasma or serum, respec-
tively) (Life Technologies, Inc.; Carlsbad, CA), according to the manufacturer’s recommenda-
tions. The isolated exosomes were characterized with NanoSight (Malvern Panalytical, Ltd.;
Malvern, UK) and by light and electron microscopy. Briefly, following isolation, exosomal pel-
lets were re-suspended in 250 μl of PBS and examined using a Malvern NanoSight NS300
equipped with a 532 nm laser light-scattering (no labelling required) analysis to determine the
size distribution and concentration of the isolated particles. Sample concentration was
adjusted until a clear image was obtained of a population of around 100 particles in the scatter-
ing volume. Three videos of 60-second duration were taken with a frame rate of 30 frames/sec-
ond, and particle movement was analyzed using Nanoparticle Tracking Analysis (NTA)
software (version NTA 3.3, Dev Build 3.3.104; NanoSight, Ltd.; Salisbury, UK). NTA analyzes
videos captured using the instrument, providing a particle size distribution and particle count
based upon tracking of each particle’s Brownian motion. Tracking is carried out for all parti-
cles in the laser-scattering volume to produce a particle size distribution using the Stokes-Ein-
stein equation, relating the Brownian motion of a particle to a sphere-equivalent
hydrodynamic radius.
For transmission electron microscopic (TEM) visualization, 50 μl exosomal solution in PBS
was fixed with 500 μl of 2% paraformaldehyde and glutaraldehyde solution. After overnight
fixation at 4˚C, exosomes were carefully loaded onto charged formvar-coated copper grids for
10 minutes, then grids were stained with 2% uranyl acetate for 1 minute, rinsed, blotted dry
and imaged at 80 kV using the FEI Tecnai™ G2 Spirit TWIN TEM (FEI Company; Hillsboro,
OR).
RNA extraction, library construction and miRNA expression
Total RNA was extracted from the exosomal fractions using the Total Exosome RNA and Pro-
tein Isolation kit (Life Technologies, Inc.) per the manufacturer’s recommendations. The RNA
was then eluted in nuclease-free water followed by quantity and quality assessment using the
Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA) and the NanoDrop 1000
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Spectrophotometer (Thermo Scientific; Wilmington, DE). To identify potential miRNA bio-
markers, we assessed the miRNA spectrum in the discovery samples using next-generation
sequencing (NGS). Small RNA sequencing libraries were constructed using the NEBNext1
Small RNA Library Prep set (New England BioLabs; Ipswich, MA) and run on NextSeq™ 500/
550 High Output kits v2.5 (Illumina; San Diego, CA) with single-end 50-nucleotide read-
length. Given the variable ages of the samples (~5–30 years), quality assurance measures were
taken (principal component analysis, Spearman correlation of mapped reads, read numbers
>1 million per sample) to assure adequate RNA quality. Data processing and miRNA mapping
were performed as described previously [15] with subsequent miRNA expression internally
normalized using read count per million (RPM) of processed read and then log2 transformed.
Differential expression analysis was performed by edgeR Bioconductor package on samples
with more than 1 million reads [16, 17]. To be considered to have a significant change in
expression, a miRNA required >2.0 fold-change (or>1.0 log2 fold-change) with a p-
value < 0.01 (calculated using the Wilcoxon rank sum test). Statistical comparisons of differ-
entially expressed (DE) miRNAs (identified when comparing the Control and CS plasma
groups or the AMI and CS serum groups) were corrected for multiple hypothesis testing based
upon the Benjamini-Hochberg procedure to reduce false discovery [18]. NGS results for spe-
cific potential biomarker miRNAs were confirmed on the corresponding validation samples
by employing Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) per-
formed using TaqMan Advanced miRNA assays (Thermo Fisher; Waltham, MA). The level of
miR-16-5p was used for normalization, as it was an invariant miRNA in the sample set (low
coefficient of variance across samples) based upon the miRNA mapping, as previously
described [15]. Relative miRNA concentrations are presented by ΔCt (cycle threshold) values
(Ctreference—Cttarget) [19]. The biological processes impacted by the DE miRNAs were deter-
mined by using the MicroRNA Enrichment Analysis and Annotation (miEAA) tool [20].
Statistics
The data were expressed as mean ± SEM, and statistical significance was based upon a value of
p� 0.05. SigmaPlot 14.0 and SYSTAT 13.0 software were used to plot the data and carry out
the analyses, respectively. The Mann-Whitney U-test (Wilcoxon Rank Sum) was employed to
compare group differences in qRT-PCR-validated samples between CS and control plasma
exosomal transcripts and between CS and AMI serum exosomal transcripts. In addition, the
U-test was used to compare the mean particle size at the distribution peak, the total concentra-
tion yield and the dynamic light scatter results from the NanoSight analyses of the extracted
exosomes for each comparative pair.
Results and discussion
Study subjects
Patient demographics are shown in Table 1 based upon the plasma and serum samples con-
forming to CS, AMI or age-matched, disease-free controls obtained as part of the previously
identified NIH-funded research studies with no significant differences between the compared
groups.
Isolated exosomal fraction
Despite the extensive and varying age of the source samples and regardless of their being
plasma or serum, exosomal isolation yielded surprisingly similar characteristic results suggest-
ing that the exosomes, in general, remained remarkably intact while frozen over time and
PLOS ONE Exosomal miRNA in cardiac sarcoidosis
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throughout the isolation process. Exosomes were relatively uniform in size and appearance
across the different samples used in the study (Fig 1). Following NanoSight analyses, there
were no apparent differences in the spectral profiles, size distribution, dynamic light scatter or
concentration yield among the study groups (S1–S3 Figs).
Sample quality assessment and miRNA detection
Given the advanced age of the samples (up to 30 years), further quality assurance measures
were taken to identify and exclude inadequate and/or poor quality samples based upon gene
expression. Principle component analysis (S4 Fig) and Spearman correlation coefficient analy-
sis of mapped reads (Fig 2) demonstrated that the samples did not present any batch effect
overall and that they were highly correlated. However, a few samples varied from the others
and reflected a comparatively poor correlation due to low sequencing depth, causing a reduced
rate of mapped reads to miRNAs (S4 Fig, Fig 2). Since this could lead to false positive results
during DE analysis, 5 of the original 40 discovery samples were excluded, largely due to their
having read numbers less than one million per sample [21, 22]. Although the overall quality of
the RNA samples was relatively good despite the extensive and varied age of the samples, the
number of miRNAs detected per sample varied with serum samples generally having fewer
than in plasma, particularly when obtained from sarcoidosis patients (S5 Fig).
DE miRNA identification and validation and resultant GO terms between
comparative groups
The raw sequence data have been deposited in NCBI’s Sequence Read Archive and are accessi-
ble through BioProject accession number PRJNA674847 (https://www.ncbi.nlm.nih.gov/sra/
PRJNA674847). For DE miRNA when comparing CS to control plasma exosomal samples,
volcano plot (S6 Fig) and heat map (Fig 3) data presented 18 transcripts that were highly sig-
nificant. Of those specifically identified (Table 2), miR-889-3p and miR-376b-3p were vali-
dated by qRT-PCR (S7 Fig). However, when comparing CS to AMI serum exosomal samples,
volcano plot (S8 Fig) and heat map (Fig 4) data provided 52 DE miRNAs. Most of those exhib-
ited higher concentrations in AMI (Table 3), of which 11 were validated by qRT-PCR (Figs 5
and 6). Many of these transcripts have been previously identified as biomarker candidates for
myocardial infarction (Fig 5), substantiating the integrity of the TIMI II samples despite their
long term frozen storage. GO term functional enrichment analysis of the DE miRNAs showing
higher concentrations in AMI yielded considerable GO terms. Table 4 lists the most
Table 1. Patient demographics.
Samples Sample Use Groups Age (years) Gender (M/F) Race (W/B/O)a
ACCESS Study (Plasma) Discovery Control (n = 10) 44.0 ± 4.8 4/6 7/3/0
Validation Control (n = 10) 43.0 ± 3.3 2/8 4/6/0
Discovery Cardiac Sarcoidosis (n = 10) 38.0 ± 3.7 5/5 6/4/0
Validation Cardiac Sarcoidosis (n = 10) 43.0 ± 2.9 5/5 6/4/0
TIMI II Trial and GRADS Study (Serum) Discovery AMIb (n = 10) 51.8 ± 4.5 5/5 9/1/0
Validation AMI (n = 10) 51.4 ± 4.4 5/5 9/1/0
Discovery Cardiac Sarcoidosis (n = 10) 51.6 ± 3.4 6/4 7/3/0
Validation Cardiac Sarcoidosis (n = 10) 57.2 ± 3.5 7/3 9/0/1
aWhite/Black/Other
bAMI = Acute myocardial infarction
https://doi.org/10.1371/journal.pone.0246083.t001
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significantly affected functional terms, including a number of them associated with cardiovas-
cular activities. Among the few identified as being more highly expressed in CS, miR-144-5p
was validated (Fig 6). As expected, there were many DE miRNAs found when comparing
plasma exosomal samples to serum exosomal samples in the CS group (S9 Fig).
This study is the first, to our knowledge, to show that circulating exosomal miRNA expres-
sion patterns can distinguish AMI from CS. Despite the advanced age of many of the samples,
Fig 1. Exosomal visualization. Representative light (A) and electron (B-E) photomicrographs of exosomes, as marked
by arrows, following isolation from plasma or serum samples from patients with cardiac sarcoidosis [scale = 1 mm (A)
and 100 nm (B-E)].
https://doi.org/10.1371/journal.pone.0246083.g001
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Fig 2. Exosomal miRNA quality determination. Quality assessment of exosomal miRNA isolated from the plasma/serum samples of the
ACCESS/TIMI II/GRADS studies following next generation sequencing analyses. Spearman correlation analysis shows overall that the samples
were highly correlated. Samples showing low correlation (blue) seemed to be related to the low read depth, which caused the reduced rate of
mapped reads to miRNA for those particular samples (shown for cardiac sarcoidosis serum samples). Thus, samples with<106 reads (5 total)
were eliminated from the final differential expression analyses.
https://doi.org/10.1371/journal.pone.0246083.g002
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exosomal miRNA expression patterns observed in AMI in this study are concordant with tran-
scripts identified in prior studies conducted on fresh plasma samples from patients with AMI
[23, 24]. When compared to AMI, a lower number of exosomal miRNAs was DE in CS
Fig 3. Plasma exosomal miRNA demonstrates differential expression between control and cardiac sarcoidosis. Heat map
demonstrating exosomal miRNA differential expression following next generation sequencing analyses of control and cardiac sarcoidosis
(CS) plasma samples. The results identified 12 up-regulated and 6 down-regulated significantly different miRs in CS relative to control
[p < 0.01 and fold-change (FC)< 0.5 or> 2].
https://doi.org/10.1371/journal.pone.0246083.g003
Table 2. MiRNA that are significantly up- or down-regulated when comparing Cardiac Sarcoidosis (CS) to normal healthy controls.
miRNA Expression: CS > Control Log2(Fold-change) p-Value miRNA Expression: Control > CS Log2(Fold-change) p-Value
hsa-miR-3187-3p 2.2 0.0006 hsa-miR-4485-5p -3.5 0.0003
hsa-miR-27a-5p 1.8 0.0014 hsa-miR-34a-5p -2.2 0.0029
hsa-miR-618-5p 1.7 0.0035 hsa-miR-135a-1-5p -2.1 0.0010
hsa-miR-1307-5p 1.6 0.0001 hsa-miR-4485-3p -1.9 0.0041
hsa-miR-21-3p 1.4 0.0006 hsa-miR-376b-3p -1.8 0.0070
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(Table 3). Several important variables likely factor into the detection of fewer DE transcripts in
CS, as explained below, but the results of these investigations are supportive of the premise
that circulating exosomal miRNA expression patterns could be used to discriminate inflamma-
tory and ischemic myocardial damage in the clinical setting.
Why should we focus on circulating exosome-derived miRNA for biomarker discovery?
One theoretical advantage of exosome-derived genetic biomarkers is their stability, which is a
product of the protection conferred by the exosomal membrane against circulating RNase
enzymes [25]. Our data strongly supports this paradigm based upon the fact that some of the
Fig 4. Serum exosomal miRNA demonstrates differential expression between cardiac sarcoidosis and acute myocardial infarction.
Heat map demonstrating exosomal miRNA differential expression following next generation sequencing analyses of cardiac sarcoidosis
(CS) and acute myocardial infarction (AMI) serum samples. The results identified 5 up-regulated and 47 down-regulated significantly
different miRs in CS compared to AMI [p< 0.01 and fold-change (FC)< 0.5 or> 2].
https://doi.org/10.1371/journal.pone.0246083.g004
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Table 3. MiRNA that are significantly up- or down-regulated when comparing Cardiac Sarcoidosis (CS) to Acute Myocardial Infarction (AMI).
miRNA Expression: CS > AMI Log2(Fold-Change) p-Value miRNA Expression: AMI > CS Log2(Fold-Change) p-Value
hsa-miR-136-5p 2.8 0.0030 hsa-miR-208b-3p -5.1 3.5 x 10−6
hsa-miR-1284-5p 2.0 0.0008 hsa-miR-7641-2-5p -3.9 0.0002
hsa-miR-624-5p 1.7 0.0035 hsa-miR-499a-5p -3.8 3.0 x 10−5
hsa-miR-144-5p 1.4 0.0015 hsa-miR-6087-3p -3.7 0.0014
hsa-miR-624-3p 1.4 0.0057 hsa-miR-584-5p -3.2 6.2 x 10−6
hsa-miR-23a-5p -3.2 5.7 x 10−5
hsa-miR-877-5p -2.9 6.1 x 10−5
hsa-miR-380-3p -2.6 0.0014
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Fig 5. Validation of some selected differentially expressed miRNA transcripts between cardiac sarcoidosis and
acute myocardial infarction serum exosomal samples. MiRNA transcripts, previously demonstrated and identified as
markers of myocardial infarction and determined to be differentially expressed by next generation sequencing, were
confirmed by qRT-PCR in the serum exosomal validation samples from the acute myocardial infarction (AMI) group
and found to be expressed at significantly higher levels when compared to those of the cardiac sarcoidosis (CS) group
(�p< 0.05).
https://doi.org/10.1371/journal.pone.0246083.g005
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Fig 6. Further selected differentially expressed miRNA transcripts between cardiac sarcoidosis and acute
myocardial infarction serum exosomal samples validated. Additional miRNA transcripts, determined to be
differentially expressed by next generation sequencing when comparing the cardiac sarcoidosis (CS) and acute
myocardial infarction (AMI) groups, were confirmed by qRT-PCR in the serum exosomal validation samples
(�p< 0.05). MiR-144-5p, previously noted as a marker of cardiomyopathy, was validated to have a significantly higher
level of expression in the CS group.
https://doi.org/10.1371/journal.pone.0246083.g006
PLOS ONE Exosomal miRNA in cardiac sarcoidosis
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TIMI II AMI samples have been in storage for over 30 years, yet the quality and quantity of
miRNA in these ancient exosomes was comparable to the relatively new GRADS CS samples
collected within the past 5–10 years (S1–S3 and S5 Figs). Another compelling advantage of
exosomal biomarkers rests upon the premise that the contents of the circulating exosomes dif-
fer from other components of the blood in that they are derived directly from diseased or dis-
ease-affected cells. This concept is supported by investigations showing distinct miRNA
populations in exosomes compared to exosome-depleted plasma [25], and other studies con-
firming regulation of miRNA expression patterns in exosomes by diseased human tissues [26].
Although we did not confirm a myocardial source of the circulating exosome-derived miRNA
in this study, prior publications have documented simultaneous elevated expression of miRs-
1, -208b and -499 in myocardium and circulating exosomes in the context of acute myocardial
infarction in humans [27], and miR-133 is expressed in cardiac and skeletal muscle [28]. Thus,
at least some of the miRNAs identified in this study are from diseased myocardium.
This study shows a particularly strong exosomal miRNA signal in AMI compared to CS. In
addition, the AMI signal is remarkably consistent with results of prior studies that focused on
plasma or tissue miRNA. We identified 47 exosomal miRNAs having increased concentrations
in AMI compared to CS serum samples (Table 3). Of these, 11 miRNA transcripts were vali-
dated by qRT-PCR (Figs 5 and 6), and 8 of these 11 have been previously linked to human
AMI {miR-1 [23]; miR-133 [23, 24]; miR-146a [28, 29]; miR-208b [23]; miR-335 [30]; miR-
423 [24]; miR-483 [31] and miR-499 [27]}. In contrast, only 5 miRNAs showed a significantly
increased concentration in CS when compared to AMI serum samples (Table 3), of which 3
have been linked to myocardial disease {miR-144 (validated, Fig 6) [32, 33], miR-624a and
miR-624b [34, 35]}.
There are several possible explanations for the weaker circulating exosomal miRNA signal
observed in the context of CS compared to AMI. The most significant variable being the
diverse phenotypes of CS, typically presenting with one or more of the following disease mani-
festations: 1) active myocardial (e.g., granulomatous) inflammation; 2) chronic myocardial
fibrosis or remodeling, and 3) disease localized to the electrical conduction pathways within
Table 4. Top 10 Gene Ontogeny (GO) biological processes enriched by down-regulated miRNAs (relevant when








0.000152 hsa-miR-148b-3p; hsa-miR-335-5p; hsa-miR-423-3p; hsa-miR-
423-5p
GO0055009, atrial cardiac muscle
tissue morphogenesis
0.000256 hsa-miR-148b-3p; hsa-miR-335-5p; hsa-miR-877-5p
GO0060214, endocardium formation 0.000256 hsa-miR-148b-3p; hsa-miR-335-5p; hsa-miR-877-5p
GO0048845, venous blood vessel
morphogenesis
0.000267 hsa-miR-130b-3p; hsa-miR-148b-3p; hsa-miR-335-5p; hsa-
miR-877-5p
GO0046676, negative regulation of
insulin secretion
0.000316 hsa-miR-130b-3p; hsa-miR-148b-3p; hsa-miR-152-3p; hsa-




0.000432 hsa-miR-130b-3p; hsa-miR-148b-3p; hsa-miR-335-5p; hsa-
miR-378a-3p
GO0051492, regulation of stress fiber
assembly
0.000432 hsa-miR-146a-5p; hsa-miR-148b-3p; hsa-miR-335-5p; hsa-
miR-584-5p
GO0010466, negative regulation of
peptidase activity
0.000623 hsa-miR-335-5p; hsa-miR-423-5p; hsa-miR-877-5p
GO0043049, otic placode formation 0.000623 hsa-miR-148b-3p; hsa-miR-335-5p; hsa-miR-877-5p
https://doi.org/10.1371/journal.pone.0246083.t004
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the heart. Another factor that likely contributes to increases in the circulating exosomal signal
during AMI is the rapid and dramatic onset of myocardial damage induced by acute ischemia
involving large portions of the heart. One of the limitations of this study was the inability to
accurately classify the CS patients based upon these very different myocardial pathological fea-
tures. For instance, for the ACCESS study conducted in the late 1990’s, CS was classified based
upon clinical features ranging from cardiac arrhythmias to heart failure. There was no objec-
tive way to characterize the specific myocardial disease features due to the lack of advanced
myocardial imaging technology at the time of the study. For the GRADS study, conducted
more recently, the detection of cardiac sarcoidosis was not standardized. In some cases, CS
detection was based upon MRI with late gadolinium enhancement, which most reliably detects
chronic fibrosis or remodeling. In other GRADS cases, CS was identified by FDG-18 PET
scan, which reliably detects active cardiac inflammation as opposed to fibrosis or remodeling.
It is reasonable to speculate that there are different circulating exosomal miRNA patterns in
those with active cardiac inflammation compared to patients with established chronic cardiac
fibrosis. Furthermore, an inflammatory biomarker would have greater clinical utility in terms
of guiding immune suppression therapies for CS. Thus, future studies should focus on the
identification of CS biomarkers that are specific for the detection of acute myocarditis.
Another limitation of the study relates to the processing of the samples, particularly as
relates to comparing results from exosomes derived from serum versus plasma. Serum and
plasma extracellular miRNA profiles are different, and serum has fewer miRNA detected over-
all, as we have demonstrated in S5 and S9 Figs, likely relating to cell stress and loss of exosomes
during clot formation [36, 37]. Plasma is preferred for this reason, and may explain why com-
mon CS miRNA were not identified when comparing CS to controls (plasma samples) and CS
to AMI (serum samples).
Conclusions
The detection of active myocardial inflammation in sarcoidosis patients is a challenge. The
clinical presentation can resemble cardiac ischemia [7–10], and definitive diagnosis of CS
requires that cardiac ischemia be excluded [38, 39]. Circulating exosomal miRNA show prom-
ise as biomarkers that can distinguish CS from AMI and with further development perhaps
other inflammatory cardiomyopathies. Future studies focusing on CS patients with radio-
graphic evidence of active inflammation or chronic fibrosis are likely to yield more reliable cir-
culating exosomal miRNA biomarkers for the detection of CS. Since circulating extracellular
miRNAs are quite stable [40], they provide promise for improved CS detection and may prove
useful for distinguishing other severe sarcoidosis phenotypes (e.g., neurosarcoidosis).
Supporting information
S1 Fig. Representative exosomal spectra following isolation in each study group sample.
Representative results from NanoSight analysis, following the isolation of the exosomal frac-
tion from the plasma/serum study samples, showing similar exosomal (particle) spectral pro-
file, size distribution and concentration.
(TIF)
S2 Fig. High degree of similarity in the exosomal distribution and yield as isolated from
samples in each study group. Group results from NanoSight analyses of the exosomes isolated
from the plasma/serum study samples demonstrating nearly identical exosomal (particle)
mean size at the distribution peak (A) along with their total concentration yield (B), despite
the relatively extensive and varying age of the samples. Results indicated that the exosomes
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remained remarkably and similarly intact while frozen over time and following isolation from
their source samples.
(TIF)
S3 Fig. Further evidence demonstrating the similarity in exosomal properties isolated
from samples in each study group. Despite the relatively extensive and varying age of the
samples, NanoSight analyses of exosomes isolated from the plasma/serum demonstrated
nearly identical dynamic light scatter results.
(TIF)
S4 Fig. Evaluation of extracted exosomal miRNA demonstrates consistent quality among
the samples in each study group. Quality assessment of exosomal miRNA isolated from the
plasma/serum samples of the ACCESS/TIMI II/GRADS studies following next generation
sequencing analyses. Principle component analysis plot shows that there was no obvious batch
effect across the samples. Three samples looked quite different from the others (orange circle)
and were ultimately eliminated from the final differential expression analyses.
(TIF)
S5 Fig. Differential number of the extracted exosomal miRNAs detected among the sam-
ples in each study group. Distribution of detected exosomal miRNAs extracted from the
plasma/serum samples. Generally, plasma samples had a higher number detected exosomal
miRNAs than serum. Within the plasma or serum samples, the sarcoid group had a lower
number of detected exosomal miRNAs than the comparative control or acute myocardial
infarction (AMI) groups, respectively.
(TIF)
S6 Fig. Differential expression of the extracted exosomal miRNAs between the cardiac sar-
coidosis and control plasma study samples. (Top) A volcano plot representing differential
expression (DE) analysis of exosomal miRNAs extracted from the cardiac sarcoid and control
plasma study samples after removal of samples with a low read depth (<106 reads). Wherein
the Y-axis corresponds to transcripts with high statistical significance (-log 10 of p-value), and
the X-axis corresponds with fold-change of gene expression (log base 2) generated from the
same data set. DE transcripts on the upper left side of the plot have strong statistical signifi-
cance with relatively low expression; whereas, transcripts on the upper right are more highly
expressed with strong statistical significance. The blue lines correspond with a fold-change of
1.5 and p-value cutoff of 0.05; red dashed lines as marked. (Bottom) DE analyses demonstrated
a number of up- and down-regulated transcripts at two levels of significance.
(TIF)
S7 Fig. Validation of selected differentially expressed miRNA transcripts between cardiac
sarcoidosis and control plasma exosomal samples. Additional miRNA transcripts [(A) miR-
889-3p and (B) miR-376-3p], determined to be differentially expressed by next generation
sequencing when comparing the cardiac sarcoidosis (CS) and control groups, were confirmed
by qRT-PCR in the plasma exosomal validation samples (�p< 0.05).
(TIF)
S8 Fig. Differential expression of the extracted exosomal miRNAs between the cardiac sar-
coidosis and acute myocardial infarction serum study samples. (Top) A volcano plot repre-
senting differential expression (DE) analysis of exosomal miRNAs extracted from the cardiac
sarcoid and acute myocardial infarction (AMI) serum study samples after removal of samples
with a low read depth (<106 reads). Wherein the Y-axis corresponds to transcripts with high
statistical significance (-log 10 of p-value), and the X-axis corresponds with fold-change of
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gene expression (log base 2) generated from the same data set. DE transcripts on the upper left
side of the plot have strong statistical significance with relatively low expression; whereas, tran-
scripts on the upper right are more highly expressed with strong statistical significance. The
blue lines correspond with a fold-change of 1.5 and p-value cutoff of 0.05; red dashed lines as
marked. (Bottom) DE analyses demonstrated a number of up- and down-regulated transcripts
at two levels of significance.
(TIF)
S9 Fig. Differential expression of the extracted exosomal miRNAs between the cardiac sar-
coidosis plasma and serum study samples. (Top) A volcano plot representing differential
expression (DE) analysis of exosomal miRNAs extracted from the cardiac sarcoid plasma and
serum study samples after removal of samples with a low read depth (<106 reads). Wherein
the Y-axis corresponds to transcripts with high statistical significance (-log 10 of p-value), and
the X-axis corresponds with fold-change of gene expression (log base 2) generated from the
same data set. DE transcripts on the upper left side of the plot have strong statistical signifi-
cance with relatively low expression; whereas, transcripts on the upper right are more highly
expressed with strong statistical significance. The blue lines correspond with a fold-change of
1.5 and p-value cutoff of 0.05; red dashed lines as marked. (Bottom) DE analyses demonstrated
a number of up- and down-regulated transcripts at two levels of significance.
(TIF)
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